Immunocore (IMCR)

Company Profile

immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body’s own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting technology with an effector technology, anti-cd3 scfv, that catalyses the killing of the targeted diseased cells by the host’s own non-specific cytotoxic t cells. immunocore is developing a portfolio of products from the platform, called immtacs, for the treatment of cancer, chronic infectious disease and diabetes.

Company profile

Ticker

IMCR

Exchange

Website

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Acorda Therapeutics ...

Former names

Immunocore Ltd

SEC CIK

0001671927

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IMCR stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

6-K

Current report (foreign)

7 Nov 23

6-K

Current report (foreign)

10 Aug 23

6-K

Current report (foreign)

14 Jul 23

6-K

Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO

5 Jun 23

6-K

Current report (foreign)

16 May 23

6-K

Current report (foreign)

10 May 23

6-K

Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival

18 Apr 23

6-K

Current report (foreign)

18 Apr 23

S-8

Registration of securities for employees

6 Apr 23

6-K

Current report (foreign)

10 Mar 23

Transcripts

IMCR

Earnings call transcript

2023 Q2

10 Aug 23

IMCR

Earnings call transcript

2022 Q4

1 Mar 23

IMCR

Earnings call transcript

2022 Q2

10 Aug 22

Latest ownership filings

View all

144

Notice of proposed sale of securities

30 Nov 23

144

Notice of proposed sale of securities

16 Nov 23

144

Notice of proposed sale of securities

6 Nov 23

144

Notice of proposed sale of securities

2 Oct 23

SC 13D/A

GENERAL ATLANTIC, L.P.

18 Sep 23

144

Notice of proposed sale of securities

25 Aug 23

144

Notice of proposed sale of securities

17 Aug 23

144

Notice of proposed sale of securities

12 Jul 23

SC 13D/A

GENERAL ATLANTIC, L.P.

15 Jun 23

144

Notice of proposed sale of securities

5 Jun 23

Financial summary

Financial statements Chart IMCR financial data

Quarter (USD)	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Immunocore earnings reports.

Institutional ownership, Q3 2023

IMCR institutional ownership history Ownership history

78.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	125	122	+2.5%
Opened positions	12	29	-58.6%
Closed positions	9	14	-35.7%
Increased positions	50	49	+2.0%
Reduced positions	37	25	+48.0%

13F shares	Current	Prev Q	Change
Total value	1.90 tn	2.06 tn	-7.9%
Total shares	39.03 mm	37.41 mm	+4.3%
Total puts	2.90 k	55.00 k	-94.7%
Total calls	212.30 k	311.90 k	-31.9%
Total put/call ratio	0.0	0.2	-92.3%

Largest owners	Shares	Value	Change
RTW Investments	6.10 mm	$316.40 bn	+1.1%
Wellington Management	3.91 mm	$203.11 bn	+5.9%
Rock Springs Capital Management	2.94 mm	$152.78 bn	-2.8%
T. Rowe Price	2.52 mm	$131.05 bn	+4.0%
Baker Bros. Advisors	2.52 mm	$130.83 bn	0.0%
FMR	2.14 mm	$110.87 bn	+4.4%
Malin Life Sciences	2.11 mm	$111.40 mm	0.0%
Paradigm Biocapital Advisors	1.38 mm	$71.87 bn	+9.0%
MS Morgan Stanley	961.09 k	$49.88 bn	+18.3%
General Atlantic	950.00 k	$49.31 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
Pictet Asset Management	0.00	-941.77 k	EXIT
Pictet Asset Management Holding	910.24 k	+910.24 k	NEW
Holocene Advisors	165.36 k	-528.61 k	-76.2%
Nicholas Investment Partners	512.86 k	+508.16 k	+10811.8%
Braidwell	906.97 k	+438.95 k	+93.8%
Avidity Partners Management	348.20 k	-226.80 k	-39.4%
Wellington Management	3.91 mm	+217.92 k	+5.9%
Polar Capital	250.00 k	+207.66 k	+490.5%
Millennium Management	189.38 k	+189.38 k	NEW
Fiera Capital	679.80 k	+158.50 k	+30.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.